Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2301-2320 of 3,900 trials

Peripheral T-Cell Lymphoma: Lacutamab with GemOx

We are studying a new treatment combining Lacutamab with GemOx for patients with relapsed or refractory peripheral T-cell lymphoma. The trial aims to evaluate its effectiveness and safety compared to GemOx alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Gastric Cancer: [18F]AlF-FAPI-74 PET/CT Study

We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.

Advanced Gastric CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal MedicineOncology

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

KO-2806 for Advanced Solid Tumors

We are studying the effects of KO-2806, both alone and with other treatments, in patients with advanced solid tumors. This research aims to find out how well it works in managing their condition.

Colorectal CancerPancreatic Ductal AdenocarcinomaRenal Cell Carcinoma>2 yearsSafety phase (I)Oncology

Scabies Treatment: Testing Permethrin Cream

We are studying the effectiveness of a new higher-concentration permethrin cream for treating scabies in adults and children. The trial aims to see if this treatment works better than the standard cream and how safe it is.

Scabies>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyInfectious Diseases

RSV Vaccination in Stem Cell Transplant Recipients

We are studying two RSV vaccines to see how well they work in patients who have received stem cell transplants. The goal is to understand their immune response and effectiveness compared to healthy individuals.

Allogeneic Hematopoietic Stem Cell Transplantation≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesInternal Medicine

Alternative Antibiotics for Resistant UTIs

We are testing new oral antibiotics for patients with febrile urinary tract infections caused by resistant bacteria. The goal is to see if these alternatives are as safe as current treatments.

Urinary Tract Infection (UTI) from Resistant Bacteria>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInfectious DiseasesUrology

Crohn's and Colitis: Stopping Anti-TNF Treatment

We are studying if specific markers can help identify patients who can safely stop their anti-TNF treatment while in remission. This may help tailor treatment plans for better health outcomes.

Ulcerative ColitisCrohn's Disease>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Advanced Solid Cancers: BAY 3498264 Study

We are investigating a new treatment for patients with advanced solid cancers that have the KRASG12C mutation. The study looks at how this treatment works alone and with another medication.

Advanced Solid Tumors with KRAS Mutation>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: CXCR4 PET Tracer Study

We are testing a new radiopharmaceutical to see how it works in patients with advanced solid tumors. This study aims to understand its effects on the body and how it can help in future treatments.

Advanced Solid Tumor6-12 monthsSafety phase (I)Oncology

Type 1 Diabetes: Diamyd Study

We are investigating whether the drug Diamyd can help preserve insulin production in adolescents and adults recently diagnosed with type 1 diabetes. The study will also look at the safety of Diamyd compared to a placebo.

Type 1 Diabetes>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

Urethral Stenosis: Innovative Fat Injection Treatment

We are studying the safety and potential benefits of injecting fat-derived cells for men with recurrent urethral stenosis after surgery. This trial aims to see if this treatment can improve symptoms and reduce the need for further procedures.

Urethral Stenosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesUrology

Breast Reconstruction Surgery: Opioid-Free vs. Opioid-Based Anesthesia

We are studying the effects of opioid-free anesthesia compared to traditional opioid-based anesthesia in patients undergoing breast reconstruction surgery. This research aims to find safer pain management options.

Anesthesia during Breast Reconstruction Surgery>2 yearsConfirmation phase (III)OncologyOtolaryngology

Relapsed or Refractory PCNSL: Emavusertib Study

We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.

Hematological MalignancyPrimary Central Nervous System Lymphoma (PCNSL)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Early-Stage Colon Cancer: NICHE Trial for Immunotherapy

We are studying a new immunotherapy treatment for patients with early-stage colon cancer to see if it can reduce tumors before surgery. The trial also aims to identify biomarkers that may help tailor treatments and improve patient outcomes.

Colon or Rectosigmoid Adenocarcinoma≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Ventilator-Associated Pneumonia: Antimicrobial Stewardship Study

We are exploring a new method for managing antibiotics in patients with Ventilator-Associated Pneumonia in intensive care. This study aims to see if daily assessments can improve survival and reduce complications.

Ventilator Associated PneumoniaIntensive Care>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Acute Pyelonephritis: Short vs. Long Antibiotic Treatment

We are studying whether a 7-day antibiotic treatment is as effective as a 14-day treatment for kidney transplant recipients with acute pyelonephritis. This research aims to improve treatment options and patient safety.

Kidney Infection (Pyelonephritis)Kidney Transplant Recipients>2 yearsMonitoring phase (IV)Standard MedicinesInfectious DiseasesNephrologyUrology

Lupus Nephritis: KYV-101 CAR T-Cell Therapy

We are testing a new immune cell therapy for individuals with refractory lupus nephritis. The goal is to see if it can improve kidney function in patients who have not responded to other treatments.

Lupus Nephritis>2 yearsSafety phase (I)Efficacy phase (II)NephrologyRheumatology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Transfusion-Dependent β-Thalassemia: CTX001 Treatment

We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.

Transfusion-Dependent Thalassemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics